EnVivo's Alpha-7 agonist set for Phase III Alzheimer's trials
This article was originally published in Scrip
Executive Summary
EnVivo Pharmaceuticals has said it will continue to advance the development of its alpha-7 agonist, EVP-6124, and plans to initiate a Phase III trial in Alzheimer's disease in 2013. This follows positive Phase IIb data for the drug.